Ricke Jens, Westphalen Christoph Benedikt, Seidensticker Max
Klinik und Poliklinik für Radiologie, LMU Klinikum, Munich, Germany.
Medizinische Klinik und Poliklinik III und CCC München, Klinikum der Universität München, LMU München, Munich, Germany.
Visc Med. 2020 Oct;36(5):359-363. doi: 10.1159/000509897. Epub 2020 Oct 5.
Clinical trials have proven a survival benefit from applying local therapies for oligometastatic cancers of various origin.
Today, the definition of oligometa-static disease is based on limited lesion numbers and organ systems involved. Treatment guidelines by the European Organisation for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO) and several other groups suggest a threshold of up to 5 tumours. Established biological markers indicating the aggressiveness of a given tumour (and therefore suggesting local treatment only or the addition of or complete switch to systemic therapies) are missing, except for disease-free survival, the only recommended parameter for patient selection beyond lesion count.
The following article discusses clinical implications as well as local techniques established for the treatment of oligometastatic disease.
临床试验已证明，对各种原发的寡转移性癌症应用局部治疗可带来生存获益。
如今，寡转移疾病的定义基于受累病灶数量和器官系统有限。欧洲癌症研究与治疗组织（EORTC）、欧洲医学肿瘤学会（ESMO）及其他几个组织的治疗指南建议肿瘤数量上限为5个。除无病生存期外，尚无既定的生物学标志物可表明特定肿瘤的侵袭性（从而仅提示局部治疗，或提示联合全身治疗或完全转为全身治疗），而无病生存期是除病灶计数外唯一推荐用于患者选择的参数。
以下文章讨论了寡转移疾病治疗的临床意义以及已确立的局部治疗技术。
